公开(公告)号：US20240115663A1

公开(公告)日：2024-04-11

申请号：US18370720

申请日：2023-09-20

申请人： ADOCIA

发明人： Olivier SOULA

IPC分类号： A61K38/28 ,  A61K38/22 ,  A61P3/04

CPC分类号： A61K38/28 ,  A61K38/22 ,  A61P3/04

摘要： A composition for treating diabetes, in particular type 1 diabetes, in a patient/person having a BMI of more than 28, in particular of more than or equal to 30 and/or an HbA1c of more than 7.6%, includes an insulin and an amylin receptor agonist. The composition can be used in a method of treating overweight and/or obesity by supporting a body weight control for at least 15 weeks in a patient having Type 1 diabetes and having a BMI of more than 28 kg/m2 and/or an HbA1c of more than 7.6%, and a method of treating Type 1 diabetes. The amylin receptor agonist may be a short-acting amylin receptor agonist such as pramlintide.

公开(公告)号：US11926618B2

公开(公告)日：2024-03-12

申请号：US17753162

申请日：2020-08-20

申请人： HINOVA PHARMACEUTICALS INC.

发明人： Wu Du ,  Yu Li ,  Haibo Li ,  Yuanwei Chen ,  Chengzhi Zhang ,  Xinghai Li

IPC分类号： C07D403/12 ,  A61K31/53 ,  A61P1/16 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P5/14 ,  A61P5/16 ,  A61P9/10 ,  C07D253/075

CPC分类号： C07D403/12 ,  C07B2200/05

摘要： A compound of formula (I) or an optical isomer thereof, and pharmaceutically acceptable salts, prodrugs, aquo-complexes or non-aqueous-solvent complexes thereof are provided. Experiments prove that, compared with a control compound MGL-3196, the compound of formula (I), which is obtained through specific substitution sites and specific substitution types, is higher in agonist activity to THR-beta and significantly improved in selectivity on THR-beta/THR-alpha. The compound can be used in preparing THR-beta agonist and drugs for treating adaption diseases (including dyslipidemia, hypercholesteremia, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease) applicable to the THR-beta agonist.

公开(公告)号：US11925660B2

公开(公告)日：2024-03-12

申请号：US17327020

申请日：2021-05-21

申请人： SIMEON INVESTMENT, INC.

发明人： Lijun Sun

IPC分类号： A61K31/736 ,  A61K9/00 ,  A61K31/718 ,  A61K31/722 ,  A61K31/729 ,  A61K31/731 ,  A61K31/732 ,  A61K31/734 ,  A61P3/04 ,  A61P3/06

CPC分类号： A61K31/736 ,  A61K9/0056 ,  A61K31/718 ,  A61K31/722 ,  A61K31/729 ,  A61K31/731 ,  A61K31/732 ,  A61K31/734 ,  A61P3/04 ,  A61P3/06

摘要： A treatment for obesity can include: providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together; and administering the superabsorbent material to a subject in an effective amount to provide a treatment for obesity in the subject. The treatment can include at least one of: reducing weight of the subject; reducing rate of weight gain in the subject; or increasing rate of weight loss in the subject. The treatment of obesity can include at least one of: reducing caloric intake into the subject; reducing caloric absorption by the gut of the subject; absorbing caloric material from the gut of the subject into the superabsorbent material; or increasing transfer of caloric material from bloodstream into gut.

公开(公告)号：US20240075010A1

公开(公告)日：2024-03-07

申请号：US18270167

申请日：2021-12-23

申请人： Texas Tech University System

发明人： Vadivel Ganapathy ,  Sathish Sivaprakassam ,  Yangzom D. Bhutia ,  Sabarish Ramachandran

IPC分类号： A61K31/405 ,  A61K9/00 ,  A61K31/198 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10

CPC分类号： A61K31/405 ,  A61K9/0053 ,  A61K31/198 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10

摘要： Embodiments of the present disclosure pertain to methods of treating or preventing a condition in a subject by administering to the subject a composition having alpha-methyl-L-tryptophan. In additional embodiments, the method further includes a step of instructing the subject to administer the composition in order to treat or prevent the condition in the subject. In some embodiments, the condition includes, without limitation, hyperglycemia, diet-induced diabetes, high-fat diet-induced diabetes, insulin resistance, metabolic syndrome, extra weight, obesity, hepatic steatosis, and combinations thereof. Additional embodiments of the present disclosure pertain to compositions for use in treating or preventing a condition in a subject. In some embodiments, the composition includes alpha-methyl-L-tryptophan.

公开(公告)号：US11911479B2

公开(公告)日：2024-02-27

申请号：US17590213

申请日：2022-02-01

申请人： Brenda K. Mann

发明人： Brenda K. Mann

IPC分类号： A61K47/38 ,  A61K9/00 ,  A61K47/34 ,  A61K45/06 ,  A61P15/02 ,  A61K47/32 ,  A61P31/04 ,  A61P3/04 ,  A61K31/565

CPC分类号： A61K47/38 ,  A61K9/0034 ,  A61K45/06 ,  A61K47/32 ,  A61K47/34 ,  A61P15/02 ,  A61P31/04 ,  A61K31/565

摘要： The vaginal hydrogel may be a composition which includes a glycosaminoglycan, a reactive molecule, and, in some embodiments, a therapeutic agent. The glycosaminoglycan and the reactive molecule may include either thiol groups or thiol reactive sites and have a pH that is within a range of a normal vaginal environment. Some of the thiol groups may interact with the vaginal mucosa and allow the hydrogel to remain in the vagina for a longer period than existing compounds intended for intravaginal administration. Therapeutic agents may be included in the composition. In these embodiments, the hydrogel acts as a vehicle which delivers the therapeutic agent.

公开(公告)号：US11903911B1

公开(公告)日：2024-02-20

申请号：US16859644

申请日：2020-04-27

申请人： Marshall University Research Corporation

发明人： Uma Sundaram

IPC分类号： A61K31/155 ,  A61P3/04 ,  C12Q1/25 ,  G01N33/68 ,  G01N33/50

CPC分类号： A61K31/155 ,  A61P3/04 ,  C12Q1/25 ,  G01N33/5044 ,  G01N33/6803 ,  G01N2333/90

摘要： Methods of treating obesity include administering to a subject in need thereof an effective amount of a therapeutic agent capable of reversing an inhibition of a Na/K-ATPase in a small intestine of a subject, such as a basolateral membrane Na/K-ATPase. Administering the therapeutic agent can further decrease an amount of glucose transport and/or decrease an amount of salt absorption in the small intestine of the subject to thereby treat the obesity. Methods for screening for a compound useful for treating obesity include contacting a small intestine cell with an effective amount of a test compound, and detecting whether an activity level of a Na/K-ATPase in the small intestine cell is increased in the presence of the test compound. The test compound is then identified as a compound useful for the treatment of obesity if the activity level of the Na/K-ATPase is increased in the presence of the test compound.

公开(公告)号：US11896574B2

公开(公告)日：2024-02-13

申请号：US16805795

申请日：2020-03-01

申请人： Boehringer Ingelheim Vetmedica GmbH

发明人： Dania Birte Reiche ,  Silke Haag-Diergarten ,  Leah Jeanette Hennings ,  Saskia Kley ,  Anne M. Traas

IPC分类号： A61K31/351 ,  A61P3/10 ,  A61K38/28 ,  A61K31/7034 ,  C07D309/10 ,  C07H7/04 ,  A61K31/7042 ,  C07D493/10 ,  C07D493/08 ,  A61P3/06 ,  A61P31/12 ,  A61K31/357 ,  A61P9/12 ,  A61K31/381 ,  A61K31/7056 ,  C07H17/02 ,  C07D335/02 ,  A61K31/35 ,  A61K47/22 ,  C07D333/12 ,  A61P5/50 ,  A61P3/04 ,  C07H17/00 ,  C07H5/10 ,  A61P3/00 ,  C07H15/203 ,  A61P29/00 ,  C07D333/56

CPC分类号： A61K31/351 ,  A61K31/35 ,  A61K31/357 ,  A61K31/381 ,  A61K31/7034 ,  A61K31/7042 ,  A61K31/7056 ,  A61K38/28 ,  A61K47/22 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P5/50 ,  A61P9/12 ,  A61P29/00 ,  A61P31/12 ,  C07D309/10 ,  C07D333/12 ,  C07D333/56 ,  C07D335/02 ,  C07D493/08 ,  C07D493/10 ,  C07H5/10 ,  C07H7/04 ,  C07H15/203 ,  C07H17/00 ,  C07H17/02

摘要： The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.

公开(公告)号：US20240034758A1

公开(公告)日：2024-02-01

申请号：US18258578

申请日：2021-12-22

申请人： MEDI & GENE

发明人： Min Jeong Shin ,  In Hyeok Jeong ,  Chan Park ,  Su Yeon Lee

IPC分类号： C07K14/47 ,  A61P3/10 ,  A61P3/04

CPC分类号： C07K14/4703 ,  A61P3/10 ,  A61P3/04 ,  A61K38/00

摘要： The present invention relates to an IF1 protein-derived peptide and a medicinal use thereof, in which the peptide suppresses appetite and inhibits lipid accumulation and differentiation of adipocytes in an obese animal model, and promotes insulin secretion and improves glucose tolerance in a diabetic animal model. Therefore, the present invention can be usefully used for anti-obesity and anti-diabetic purposes.

公开(公告)号：US20240034725A1

公开(公告)日：2024-02-01

申请号：US18477050

申请日：2023-09-28

申请人： Pfizer Inc.

发明人： Gary Erik Aspnes ,  Scott W. Bagley ,  John M. Curto ,  Matthew S. Dowling ,  David Edmonds ,  Mark E. Flanagan ,  Kentaro Futatsugi ,  David A. Griffith ,  Kim Huard ,  Gajendra Ingle ,  Wenhua Jiao ,  Chris Limberakis ,  Alan M. Mathiowetz ,  David W. Piotrowski ,  Roger B. Ruggeri

IPC分类号： C07D401/14 ,  A61K31/496 ,  A61K31/4545 ,  C07D487/04 ,  A61P3/00 ,  A61P15/10 ,  A61P17/06 ,  A61P9/10 ,  A61P19/06 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  A61P1/16 ,  A61P25/02 ,  A61P3/04 ,  A61P19/02 ,  A61P3/10 ,  A61P13/12 ,  A61P25/18 ,  A61P1/00 ,  A61P15/00 ,  A61P25/16 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04

CPC分类号： C07D401/14 ,  A61K31/496 ,  A61K31/4545 ,  C07D487/04 ,  A61P3/00 ,  A61P15/10 ,  A61P17/06 ,  A61P9/10 ,  A61P19/06 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  A61P1/16 ,  A61P25/02 ,  A61P3/04 ,  A61P19/02 ,  A61P3/10 ,  A61P13/12 ,  A61P25/18 ,  A61P1/00 ,  A61P15/00 ,  A61P25/16 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04

摘要： Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US20240024389A1

公开(公告)日：2024-01-25

申请号：US18323235

申请日：2023-05-24

申请人： Pouda Biotech LLC

发明人： Jun ZHANG ,  Xin XIE

IPC分类号： A61K35/747 ,  C12N1/20 ,  A61P3/06 ,  A61P9/10 ,  A61P3/04

CPC分类号： A61K35/747 ,  C12N1/205 ,  A61P3/06 ,  A61P9/10 ,  A61P3/04 ,  C12R2001/25

摘要： Provided are a Lactobacillus plantarum strain, Lactobacillus plantarum PDG8, and a composition thereof. Also provided are methods using Lactobacillus plantarum PDG8 or a composition thereof for treating a cardiovascular disease such as atherosclerosis.